Journal of Advanced Research · 2022 · 18 citations · 31 references
MedicineOncologyPharmacologyMolecular OncologyProteomicsTumor ProgressionColorectal CancerMetastatic Signaling PathwaysMolecular Tumor ProfilingProteomic ProfilingTargeted Cancer TherapyTherapeutic ResistanceAdaptive Signaling ResponsesAnnexin V AssaysCancer Metastasis MechanismsErk SignalingInhibitor ScreeningRaf-mek-erk SignalingResistance Mechanism ProteomicsTherapeutic Resistance Mechanisms
INTRODUCTION: Acquired resistance to BRAF inhibitor vemurafenib is frequently observed in metastatic colorectal cancer (CRC), and it is a thorny issue that results in treatment failure. As adaptive responses for vemurafenib treatment, a series of cellular bypasses are response for the adaptive feedback reactivation of ERK signaling, which warrant further investigation. OBJECTIVES: We identified ARF1 (ADP-ribosylation factor 1) as a novel regulator of both vemurafenib resistance and cancer metastasis, its molecular mechanism and potential inhibitor were investigated in this study. METHODS: DIA-based quantitative proteomics and RNA-seq were performed to systematic analyze the profiling of vemurafenib-resistant RKO cells (RKO-VR) and highly invasive RKO cells (RKO-I8), respectively. Co‑immunoprecipitation assay was performed to detect the interaction of ARF1 and IQGAP1 (IQ-domain GTPase activating protein 1). An ELISA-based drug screen system on FDA-approved drug library was established to screen the compounds against the interaction of ARF1-IQGAP1.The biological functions of ARF1 and LY2835219 were determined by transwell, western blotting, Annexin V-FITC/PI staining and in vivo experimental metastasis assays. RESULTS: We found that ARF1 strongly interacted with IQGAP1 to activate ERK signaling in VR and I8 CRC cells. Deletion of IQGAP1 or inactivation of ARF1 (ARF-T48S) restored the invasive ability induced by ARF1. As ARF1-IQGAP1 interaction is essential for ERK activation, we screened LY2835219 as novel inhibitor of ARF1-IQGAP1 interaction, which inactivated ERK signaling and suppressed CRC metastasis and vemurafenib-resistance in vitro and in vivo with no observed side effect. Furthermore, LY2835219 in combined treatment with vemurafenib exerted significantly inhibitory effect on ARF1-mediated cancer metastasis than used independently. CONCLUSION: This study uncovers that ARF1-IQGAP1 interaction-mediated ERK signaling reactivation is critical for vemurafenib resistance and cancer metastasis, and that LY2835219 is a promising therapeutic agent for CRC both as a single agent and in combination with vemurafenib.
31
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad, Chong Sun, Sidong Huang et al. · Nature · 2012 · 2.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations
Medicine, Oncology, Pharmacology +14
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Swarnali Acharyya, Thórdur Óskarsson, Sakari Vanharanta et al. · Cell · 2012 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +10